Literature DB >> 10861791

Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration.

F Angelucci1, A A Mathé, L Aloe.   

Abstract

The antipsychotics haloperidol and risperidone are widely used in the therapy of schizophrenia. The former drug mainly acts on the dopamine (DA) D(2) receptor whereas risperidone binds to both DA and serotonin (5HT) receptors, particularly in the neurons of striatal and limbic structures. Recent evidence suggests that neurotrophins might also be involved in antipsychotic action in the central nervous system (CNS). We have previously reported that haloperidol and risperidone significantly affect brain nerve growth factor (NGF) level suggesting that these drugs influence the turnover of endogenous growth factors. Brain-derived neurotrophic factor (BDNF) supports survival and differentiation of developing and mature brain DA neurons. We hypothesized that treatments with haloperidol or risperidone will affect synthesis/release of brain BDNF and tested this hypothesis by measuring BDNF and TrkB in rat brain regions after a 29-day-treatment with haloperidol or risperidone added to chow. Drug treatments had no effects on weight of brain regions. Chronic administration of these drugs, however, altered BDNF synthesis or release and expression of TrkB-immunoreactivity within the brain. Both haloperidol and risperidone significantly decreased BDNF concentrations in frontal cortex, occipital cortex and hippocampus and decreased or increased TrkB receptors in selected brain structures. Because BDNF can act on a variety of CNS neurons, it is reasonable to hypothesize that alteration of brain level of this neurotrophin could constitute one of the mechanisms of action of antipsychotic drugs. These observations also support the possibility that neurotrophic factors play a role in altered brain function in schizophrenic disorders. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861791     DOI: 10.1002/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  34 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

2.  Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.

Authors:  Ashley Tsai; Ying-Jay Liou; Chen-Jee Hong; Chia-Liang Wu; Shih-Jen Tsai; Ya Mei Bai
Journal:  Neuromolecular Med       Date:  2011-09-29       Impact factor: 3.843

Review 3.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 5.  Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.

Authors:  Fabio Fumagalli; Angelisa Frasca; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.

Authors:  Shuichi Chiba; Tadahiro Numakawa; Midori Ninomiya; Hyung Shin Yoon; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

Review 7.  Genetically mediated brain abnormalities in schizophrenia.

Authors:  Larry J Seidman; Heidi E Wencel
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 8.  BDNF-TrkB signaling and neuroprotection in schizophrenia.

Authors:  Chirayu D Pandya; Ammar Kutiyanawalla; Anilkumar Pillai
Journal:  Asian J Psychiatr       Date:  2012-11-03

Review 9.  [Brain-derived neurotrophic factor: from nerve growth factor to modulator of brain plasticity in cognitive processes and psychiatric diseases].

Authors:  C Laske; G W Eschweiler
Journal:  Nervenarzt       Date:  2006-05       Impact factor: 1.214

10.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.